Table 5. Comparison of clinical features between increased MAF group and decreased MAF group.
| Clinicopathologic parameters | Increased group (n=17) | Decreased group (n=36) | P value* | ||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Tumor size | 0.267 | ||||
| <5 cm | 2 | 3.8 | 9 | 17.0 | |
| ≥5 cm | 15 | 28.3 | 27 | 50.9 | |
| Tumor number | 0.158 | ||||
| Single | 5 | 9.4 | 18 | 34.0 | |
| Multiple | 12 | 22.6 | 18 | 34.0 | |
| MVI | 0.016 | ||||
| No | 0 | 0 | 10 | 18.9 | |
| Yes | 17 | 32.1 | 26 | 49.0 | |
| Tumor encapsulation | 0.335 | ||||
| No | 9 | 17.0 | 14 | 26.4 | |
| Yes | 8 | 15.1 | 22 | 41.5 | |
| Edmonson grade | 0.066 | ||||
| I + II | 9 | 17.0 | 28 | 52.8 | |
| III + IV | 8 | 15.1 | 8 | 15.1 | |
| Recurrence | <0.001 | ||||
| No | 1 | 1.9 | 21 | 39.6 | |
| Yes | 16 | 30.2 | 15 | 28.3 | |
*, analysis by two-sided Pearson’s Chi-square test, with P<0.05 considered significant. MAF, mutant allele frequency.